MAKE PROTECTION YOUR SUPERPOWER
Elevate your expertise
at PRIME.
Discover the role of SGLT2 inhibitors in enhancing
cardiorenal metabolic health and patient outcomes.
PRIME Summit 2
From screening to protection: Advancing cardiorenal metabolic care with SGLT2 inhibitors
27-28 July 2024 | Grand Intercontinental Parnas, Seoul, South Korea
PRIME Summit 2 : Post event video day 2
Speakers
Merlin Thomas
Endocrinologist
Monash University
Australia
Javed Butler
Cardiologist
Baylor Scott and White Research Institute
United States
Jeong Hyun Park
Endocrinologist
Inje University Busan Paik Hospital
Korea
Mi-kyung Kim
Endocrinologist
Haeundae Paik Hospital, Inje University
Korea
| Timestamp | Topic | Speaker |
|---|---|---|
| Introduction | Co-Chairs: Jeong Hyun Park | |
| Bench to bedside: Slowing kidney disease progression with SGLT2 inhibitors | Merlin Thomas | |
| Integrating the latest guidelines for HF management with SGLT2 inhibitor | Javed Butler | |
| Live Q & A | Moderator: Merlin Thomas Panelists: Jeong Hyun Park Mi-kyung Kim Javed Butler | |
| Case discussion: Decoding HFpEF + HFrEF | Javed Butler | |
| Live Q & A | Moderator: Merlin Thomas Panelists: Jeong Hyun Park Mi-kyung Kim Javed Butler |
Related Content
02:13:04
PRIME Summit 2 : Post event video day 1
Heart Failure 360: Early protection for every heart failure patient
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)